Spinecraft, LLC
$18.2M 27 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Sun Pharmaceutical Industries Inc.
Sun Pharmaceutical Industries Inc. reported $18,275,823.78 across General Payments, Research, and Ownership to 77,951 physicians and teaching hospitals across 80,737 transactions.
- $18.3M
- All-tracks total
- 80,737
- Transactions
- 77,951
- Recipients
- −$505.2K
- General Payments vs PY2023
Sun Pharmaceutical Industries Inc. reported $18,275,823.78 across all CMS Open Payments tracks (General + Research + Ownership) to 77,951 physicians and teaching hospitals in Program Year 2024 - ranking #99 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $6,263,040.81, averaging $234.45 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer sun-pharmaceutical-industries-inc Sun Pharmaceutical Industries Inc.
$18.3M · #99/1,925 · 0.1% industry · PY2024
- TOT $18.3M
- RANK #99
- SHARE 0.1%
- TXN 80,737
- RCP 77,951
- CAT 5
- GEN $6.3M
- ΔGEN −$505.2K
- TOP1 2.2%
- PY 2024
Volume peers
Nearest volume peer: Spinecraft, LLC ($18.2M)
Sun Pharmaceutical Industries Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Sun Pharmaceutical Industries Inc.'s CMS-reported General Payments decreased by $505.2K (−7.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SUN PHARMACEUTICAL INDUSTRIES INC.PY2023: SUN PHARMACEUTICAL INDUSTRIES INC.PY2024: SUN PHARMACEUTICAL INDUSTRIES INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $6,768,219.87
- PY2024
- $6,263,040.81
What the Data Shows for Sun Pharmaceutical Industries Inc.
Rank #99 of 1,925 companies in CMS Open Payments for 2024 belongs to Sun Pharmaceutical Industries Inc., which reported $18,275,823.78 across 80,737 transactions to 77,951 recipients - representing 0.1% of all industry payments reported nationwide for the year. Averages work out to $226.36 per transaction and $234.45 per recipient.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $2.8M, accounting for 44.7% of this company's General Payments and 863 transactions.
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Sun Pharmaceutical Industries Inc.'s 5-category general-payment breakdown at $2.8M, 44.7% of the reported total.
Sun Pharmaceutical Industries Inc. reports 5 general-payment categories - the top three are Compensation for Services Other Than Consulting (44.7%), Food and Beverage (30.0%), and Consulting Fee (17.3%). The remaining 2 categories make up 8.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Sun Pharmaceutical Industries Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $2.8M | 863 | 44.7% |
| Food and Beverage | $1.9M | 73,726 | 30.0% |
| Consulting Fee | $1.1M | 227 | 17.3% |
| Travel and Lodging | $339.1K | 1,164 | 5.4% |
| Education | $165.2K | 1,971 | 2.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $542,612.29 (8.7%) of $6,263,040.81 in this company's General Payments records across 21,852 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Sun Pharmaceutical Industries Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Cory Rubin
$135,935.17 across 119 reported transactions
- 2
Hilary Baldwin
$119,175.26 across 76 reported transactions
- 3
James Wharton
$101,484.77 across 94 reported transactions
- 4
Omar Noor
$97,515.53 across 57 reported transactions
- 5
Leon Kircik
$88,501.56 across 25 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Sun Pharmaceutical Industries Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Sun Pharmaceutical Industries Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Sun Pharmaceutical Industries Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
UCB, Inc.
$18.5M 154,022 recipients
Compare payment profiles
CSL Plasma Inc.
$17.9M 12,905 recipients
Compare payment profiles
Ultragenyx Pharmaceutical Inc.
$17.8M 2,488 recipients
Compare payment profiles
Neurocrine Biosciences, Inc.
$18.7M 100,133 recipients
Compare payment profiles
Becton, Dickinson and Company
$17.8M 12,620 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.